Current  ||| S:0 E:8 ||| JJ
and  ||| S:8 E:12 ||| CC
future  ||| S:12 E:19 ||| JJ
medical  ||| S:19 E:27 ||| JJ
treatments  ||| S:27 E:38 ||| NNS
for  ||| S:38 E:42 ||| IN
menometrorrhagia  ||| S:42 E:59 ||| NN
during  ||| S:59 E:66 ||| IN
the  ||| S:66 E:70 ||| DT
premenopause  ||| S:70 E:83 ||| FW
Excessive  ||| S:83 E:93 ||| FW
menstrual  ||| S:93 E:103 ||| FW
bleeding  ||| S:103 E:112 ||| FW
reflects  ||| S:112 E:121 ||| FW
aberrant  ||| S:121 E:130 ||| FW
angiogenesis ||| S:130 E:142 ||| FW
,  ||| S:142 E:144 ||| ,
generally  ||| S:144 E:154 ||| RB
due  ||| S:154 E:158 ||| JJ
to  ||| S:158 E:161 ||| TO
submucosal  ||| S:161 E:172 ||| VB
myomas  ||| S:172 E:179 ||| NNS
and  ||| S:179 E:183 ||| CC
endometrial  ||| S:183 E:195 ||| JJ
polyps ||| S:195 E:201 ||| NNS
,  ||| S:201 E:203 ||| ,
although  ||| S:203 E:212 ||| IN
it  ||| S:212 E:215 ||| PRP
is  ||| S:215 E:218 ||| VBZ
also  ||| S:218 E:223 ||| RB
frequently  ||| S:223 E:234 ||| RB
observed  ||| S:234 E:243 ||| VBN
with  ||| S:243 E:248 ||| IN
long-term  ||| S:248 E:258 ||| JJ
progestin-only  ||| S:258 E:273 ||| JJ
contraception ||| S:273 E:286 ||| NN
,  ||| S:286 E:288 ||| ,
impaired  ||| S:288 E:297 ||| JJ
haemostasis  ||| S:297 E:309 ||| NN
and  ||| S:309 E:313 ||| CC
hormonal  ||| S:313 E:322 ||| JJ
disorders ||| S:322 E:331 ||| NNS
.  ||| S:331 E:333 ||| .
Surgery  ||| S:333 E:341 ||| NN
( ||| S:341 E:342 ||| -LRB-
hysterectomy ||| S:342 E:354 ||| UH
,  ||| S:354 E:356 ||| ,
endometrial  ||| S:356 E:368 ||| JJ
ablation ||| S:368 E:376 ||| NN
)  ||| S:376 E:378 ||| -RRB-
is  ||| S:378 E:381 ||| VBZ
used  ||| S:381 E:386 ||| VBN
too  ||| S:386 E:390 ||| RB
frequently ||| S:390 E:400 ||| RB
.  ||| S:400 E:402 ||| .
Uterine  ||| S:402 E:410 ||| JJ
artery  ||| S:410 E:417 ||| NN
embolisation  ||| S:417 E:430 ||| NN
is  ||| S:430 E:433 ||| VBZ
also  ||| S:433 E:438 ||| RB
an  ||| S:438 E:441 ||| DT
option  ||| S:441 E:448 ||| NN
for  ||| S:448 E:452 ||| IN
myomas ||| S:452 E:458 ||| NN
.  ||| S:458 E:460 ||| .
Medical  ||| S:460 E:468 ||| JJ
treatments  ||| S:468 E:479 ||| NNS
include  ||| S:479 E:487 ||| VBP
combined  ||| S:487 E:496 ||| VBN
oral  ||| S:496 E:501 ||| JJ
contraception ||| S:501 E:514 ||| NN
,  ||| S:514 E:516 ||| ,
progestins  ||| S:516 E:527 ||| NN
and  ||| S:527 E:531 ||| CC
levonorgestrel-releasing  ||| S:531 E:556 ||| NNP
Intrauterine  ||| S:556 E:569 ||| NNP
System ||| S:569 E:575 ||| NNP
.  ||| S:575 E:577 ||| .
Gonadotropin-releasing  ||| S:577 E:600 ||| JJ
hormone  ||| S:600 E:608 ||| NN
agonists  ||| S:608 E:617 ||| NNS
provide  ||| S:617 E:625 ||| VBP
significant  ||| S:625 E:637 ||| JJ
improvements  ||| S:637 E:650 ||| NNS
in  ||| S:650 E:653 ||| IN
bleeding  ||| S:653 E:662 ||| VBG
for  ||| S:662 E:666 ||| IN
myomas ||| S:666 E:672 ||| NN
,  ||| S:672 E:674 ||| ,
but  ||| S:674 E:678 ||| CC
also  ||| S:678 E:683 ||| RB
decrease  ||| S:683 E:692 ||| VB
estrogen  ||| S:692 E:701 ||| JJ
secretion  ||| S:701 E:711 ||| NNS
( ||| S:711 E:712 ||| -LRB-
e.g.  ||| S:712 E:717 ||| CD
hot  ||| S:717 E:721 ||| JJ
flushes ||| S:721 E:728 ||| NN
,  ||| S:728 E:730 ||| ,
decreased  ||| S:730 E:740 ||| VBD
bone  ||| S:740 E:745 ||| JJ
mass ||| S:745 E:749 ||| NN
) ||| S:749 E:750 ||| -RRB-
.  ||| S:750 E:752 ||| .
Progestins ||| S:752 E:762 ||| NNP
,  ||| S:762 E:764 ||| ,
although  ||| S:764 E:773 ||| IN
used  ||| S:773 E:778 ||| VBN
widely ||| S:778 E:784 ||| RB
,  ||| S:784 E:786 ||| ,
remain  ||| S:786 E:793 ||| VBP
poorly  ||| S:793 E:800 ||| RB
effective  ||| S:800 E:810 ||| JJ
as  ||| S:810 E:813 ||| IN
they  ||| S:813 E:818 ||| PRP
promote  ||| S:818 E:826 ||| VBP
myoma  ||| S:826 E:832 ||| JJ
cell  ||| S:832 E:837 ||| NN
growth ||| S:837 E:843 ||| NN
.  ||| S:843 E:845 ||| .
Recently ||| S:845 E:853 ||| RB
,  ||| S:853 E:855 ||| ,
Selective  ||| S:855 E:865 ||| NNP
Progesterone  ||| S:865 E:878 ||| NNP
Receptor  ||| S:878 E:887 ||| NNP
Modulators  ||| S:887 E:898 ||| NNP
( ||| S:898 E:899 ||| -LRB-
SPRMs ||| S:899 E:904 ||| NNP
)  ||| S:904 E:906 ||| -RRB-
have  ||| S:906 E:911 ||| VBP
been  ||| S:911 E:916 ||| VBN
shown  ||| S:916 E:922 ||| VBN
to  ||| S:922 E:925 ||| TO
induce  ||| S:925 E:932 ||| VB
amenorrhea  ||| S:932 E:943 ||| FW
whilst  ||| S:943 E:950 ||| FW
maintaining  ||| S:950 E:962 ||| FW
endogenous  ||| S:962 E:973 ||| FW
estrogen  ||| S:973 E:982 ||| FW
secretion ||| S:982 E:991 ||| FW
.  ||| S:991 E:993 ||| .
Phase  ||| S:993 E:999 ||| NNP
II  ||| S:999 E:1002 ||| NNP
studies  ||| S:1002 E:1010 ||| NNS
have  ||| S:1010 E:1015 ||| VBP
also  ||| S:1015 E:1020 ||| RB
demonstrated  ||| S:1020 E:1033 ||| VBD
decreased  ||| S:1033 E:1043 ||| VBN
fibroid  ||| S:1043 E:1051 ||| JJ
size  ||| S:1051 E:1056 ||| NN
in  ||| S:1056 E:1059 ||| IN
SPRM-treated  ||| S:1059 E:1072 ||| JJ
women ||| S:1072 E:1077 ||| NNS
.  ||| S:1077 E:1079 ||| .
Although  ||| S:1079 E:1088 ||| IN
the  ||| S:1088 E:1092 ||| DT
mechanism  ||| S:1092 E:1102 ||| NN
of  ||| S:1102 E:1105 ||| IN
amenorrhea  ||| S:1105 E:1116 ||| NN
observed  ||| S:1116 E:1125 ||| VBD
after  ||| S:1125 E:1131 ||| IN
SPRM  ||| S:1131 E:1136 ||| NNP
treatment  ||| S:1136 E:1146 ||| NN
is  ||| S:1146 E:1149 ||| VBZ
still  ||| S:1149 E:1155 ||| RB
poorly  ||| S:1155 E:1162 ||| RB
understood ||| S:1162 E:1172 ||| VBN
,  ||| S:1172 E:1174 ||| ,
they  ||| S:1174 E:1179 ||| PRP
may  ||| S:1179 E:1183 ||| MD
control  ||| S:1183 E:1191 ||| VB
uterine  ||| S:1191 E:1199 ||| JJ
bleeding  ||| S:1199 E:1208 ||| NN
via  ||| S:1208 E:1212 ||| IN
a  ||| S:1212 E:1214 ||| DT
direct  ||| S:1214 E:1221 ||| JJ
effect  ||| S:1221 E:1228 ||| NN
on  ||| S:1228 E:1231 ||| IN
endometrial  ||| S:1231 E:1243 ||| JJ
blood  ||| S:1243 E:1249 ||| NN
vessels ||| S:1249 E:1256 ||| NNS
.  ||| S:1256 E:1258 ||| .
Suppression  ||| S:1258 E:1270 ||| NN
of  ||| S:1270 E:1273 ||| IN
bleeding  ||| S:1273 E:1282 ||| VBG
in  ||| S:1282 E:1285 ||| IN
women  ||| S:1285 E:1291 ||| NNS
with  ||| S:1291 E:1296 ||| IN
uterine  ||| S:1296 E:1304 ||| JJ
fibroids  ||| S:1304 E:1313 ||| NNS
receiving  ||| S:1313 E:1323 ||| VBG
SPRMs  ||| S:1323 E:1329 ||| NN
is  ||| S:1329 E:1332 ||| VBZ
associated  ||| S:1332 E:1343 ||| VBN
with  ||| S:1343 E:1348 ||| IN
moderate  ||| S:1348 E:1357 ||| JJ
reductions  ||| S:1357 E:1368 ||| NNS
in  ||| S:1368 E:1371 ||| IN
uterine  ||| S:1371 E:1379 ||| JJ
artery  ||| S:1379 E:1386 ||| NN
blood  ||| S:1386 E:1392 ||| NN
flow ||| S:1392 E:1396 ||| NN
,  ||| S:1396 E:1398 ||| ,
without  ||| S:1398 E:1406 ||| IN
major  ||| S:1406 E:1412 ||| JJ
changes  ||| S:1412 E:1420 ||| NNS
in  ||| S:1420 E:1423 ||| IN
angiogenic  ||| S:1423 E:1434 ||| JJ
factors  ||| S:1434 E:1442 ||| NNS
and  ||| S:1442 E:1446 ||| CC
extracellular  ||| S:1446 E:1460 ||| JJ
matrix  ||| S:1460 E:1467 ||| JJ
composition ||| S:1467 E:1478 ||| NN
;  ||| S:1478 E:1480 ||| :
a  ||| S:1480 E:1482 ||| DT
clear  ||| S:1482 E:1488 ||| JJ
difference  ||| S:1488 E:1499 ||| NN
to  ||| S:1499 E:1502 ||| TO
modifications  ||| S:1502 E:1516 ||| VB
observed  ||| S:1516 E:1525 ||| VBN
with  ||| S:1525 E:1530 ||| IN
progestins ||| S:1530 E:1540 ||| NN
.  ||| S:1540 E:1542 ||| .
These  ||| S:1542 E:1548 ||| DT
data  ||| S:1548 E:1553 ||| NNS
suggest  ||| S:1553 E:1561 ||| VBP
major  ||| S:1561 E:1567 ||| JJ
progress  ||| S:1567 E:1576 ||| NN
in  ||| S:1576 E:1579 ||| IN
the  ||| S:1579 E:1583 ||| DT
treatment  ||| S:1583 E:1593 ||| NN
of  ||| S:1593 E:1596 ||| IN
excessive  ||| S:1596 E:1606 ||| JJ
menstrual  ||| S:1606 E:1616 ||| JJ
bleeding ||| S:1616 E:1624 ||| NN
.  ||| S:1624 E:1626 ||| .
